Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study)
Overview
- Phase
- Phase 2
- Intervention
- PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
- Conditions
- Esophageal Squamous Cell Carcinomas
- Sponsor
- Shanghai Chest Hospital
- Enrollment
- 54
- Primary Endpoint
- Disease-free Survival (DFS)
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of esophageal squamous cell carcinoma patients nonresponding to initial neoadjuvant chemoradiotherapy. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.
Investigators
Jun Liu
associate proffessor
Shanghai Chest Hospital
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with Stage II/III carcinoma of the esophagus squamous cell carcinoma.
- •Completed pre-operative chemoradiotherapy followed by surgery
- •Diagnosed with residual pathologic disease after being surgically rendered free of
- •Disease with negative margins following complete resection
- •Nonresponding to initial neoadjuvant Chemoradiotherapy(TRG3 and TRG4)
Exclusion Criteria
- •Known or suspected history of active autoimmune diseases, autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
- •Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency disease, or history of organ transplantation and bone marrow transplantation；
- •Interstitial lung disease, drug-induced pneumonia, radiation pneumonitis requiring steroid therapy or active pneumonia with clinical symptoms or severe pulmonary dysfunction；
- •There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina (3) myocardial infarction within 24 weeks (4) clinical need for treatment or Interventional supraventricular or ventricular arrhythmia；
- •Have a tendency to hereditary bleeding or coagulopathy. Clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood++ and above；
- •Has not fully recovered from toxicity and/or complications from any intervention prior to initiation of treatment (i.e., ≤ grade 1 or level required at baseline, excluding fatigue or hair loss);
- •Allergic reactions to test drugs for this application；
- •Pregnant or lactating women； Those whom the investigator considered unsuitable for inclusion。
Arms & Interventions
experimental arm
PF regimen (cis-platinum of 75mg/m2/d, d1; 5-fluorouracil of 600mg/m2d1-4) combined with PD-1 inhibitors（pembrolizumab，200mg d1） every 3 weeks for 4 cycles followed by PD-1 inhibitors（pembrolizumab，200mg d1）every 3 weeks up to 2 years in a standard manner.
Intervention: PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
Outcomes
Primary Outcomes
Disease-free Survival (DFS)
Time Frame: up to approximately 46 months
Disease-free survival is defined as the time between date of surgery and first date of recurrence or death, whichever occurs first.Recurrence is defined as the appearance of one or more new lesions, which can be local, regional, or distant in location from the primary resected site ( assessed by imaging or pathology). All deaths without prior recurrence are considered as DFS events.
Secondary Outcomes
- Overall survival (OS)(up to approximately 46 months)
- Overall Survival Rate(From date of surgery to 1, 2 and 3 years later)